https://www.selleckchem.com/pr....oducts/ly3295668.htm
08; 95% CI 0.02-0.14), whereas the difference was not significant in gefitinib toxicity including rash (RR 0.90; 95% CI 0.58-1.40, P = 0.65), diarrhea (RR 1.04; 95% CI 0.66-1.64, P = 0.88), and liver injury (RR 1.00; 95% CI 0.58-1.73, P = 1.0, CD3 cells (WMD = 1.16; 95% CI -2.64-4.97) and CD8 cells (WMD = 6.78; 95% CI -1.68-15.23). Co-use of KLT injection and gefitinib may benefit the patients with NSCLC through enhancing the therapeutic effectiveness compared with gefitinib alone. To confirm these results, further rigorously design
Like
Comment
Share
